Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - DNIB UNWIND, INC.Financial_Report.xls
EX-10.2 - EX-10.2 - DNIB UNWIND, INC.d723717dex102.htm
EX-31.2 - EX-31.2 - DNIB UNWIND, INC.d723717dex312.htm
EX-32.1 - EX-32.1 - DNIB UNWIND, INC.d723717dex321.htm
EX-31.1 - EX-31.1 - DNIB UNWIND, INC.d723717dex311.htm
10-Q - FORM 10-Q - DNIB UNWIND, INC.d723717d10q.htm
EX-10.1 - EX-10.1 - DNIB UNWIND, INC.d723717dex101.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrew Hirsch, Chief Operating Officer and Chief Financial Officer of BIND Therapeutics, Inc. (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

  (1) The Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2014 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

August 7, 2014    

/s/ Andrew Hirsch

    Andrew Hirsch
   

Chief Operating Officer and Chief Financial Officer

(Principal Financial Officer)